Intermittent low‑dose digoxin may be effective and safe in patients with chronic heart failure undergoing maintenance hemodialysis

Li,Xiaozhao; Ao,Xiang; Liu,Qiong; Yang,Jinghua; Peng,Weisheng; Tang,Rong; Zhong,Yong; Meng,Ting; Gan,Lu; Zhou,Qiaoling

doi:10.3892/etm.2014.2013

December-2014 Volume 8 Issue 6

Full Size Image

Journals

International Journal of Molecular Medicine

International Journal of Molecular Medicine is an international journal devoted to molecular mechanisms of human disease.

International Journal of Oncology

International Journal of Oncology is an international journal devoted to oncology research and cancer treatment.

Molecular Medicine Reports

Covers molecular medicine topics such as pharmacology, pathology, genetics, neuroscience, infectious diseases, molecular cardiology, and molecular surgery.

Oncology Reports

Oncology Reports is an international journal devoted to fundamental and applied research in Oncology.

Experimental and Therapeutic Medicine

Experimental and Therapeutic Medicine is an international journal devoted to laboratory and clinical medicine.

Oncology Letters

Oncology Letters is an international journal devoted to Experimental and Clinical Oncology.

Biomedical Reports

Explores a wide range of biological and medical fields, including pharmacology, genetics, microbiology, neuroscience, and molecular cardiology.

Molecular and Clinical Oncology

International journal addressing all aspects of oncology research, from tumorigenesis and oncogenes to chemotherapy and metastasis.

World Academy of Sciences Journal

Multidisciplinary open-access journal spanning biochemistry, genetics, neuroscience, environmental health, and synthetic biology.

International Journal of Functional Nutrition

Open-access journal combining biochemistry, pharmacology, immunology, and genetics to advance health through functional nutrition.

International Journal of Epigenetics

Publishes open-access research on using epigenetics to advance understanding and treatment of human disease.

Medicine International

An International Open Access Journal Devoted to General Medicine.

December-2014 Volume 8 Issue 6

Full Size Image

Article Open Access

Intermittent low‑dose digoxin may be effective and safe in patients with chronic heart failure undergoing maintenance hemodialysis

Authors:
- Xiaozhao Li
- Xiang Ao
- Qiong Liu
- Jinghua Yang
- Weisheng Peng
- Rong Tang
- Yong Zhong
- Ting Meng
- Lu Gan
- Qiaoling Zhou
View Affiliations / Copyright

Affiliations: Department of Nephrology, Xiangya Hospital of Central South University, Changsha, Hunan 410008, P.R. China, Department of Nephrology, Xiangya Hospital of Central South University, Changsha, Hunan 410008, P.R. China, Department of Cardiology, Xiangya Hospital of Central South University, Changsha, Hunan 410008, P.R. China
Pages: 1689-1694
|
Published online on: October 9, 2014

https://doi.org/10.3892/etm.2014.2013
Expand metrics +

Abstract

A low dose of digoxin is known to reduce mortality and hospitalization in patients with heart failure; however, the safety of digoxin in treating patients with heart failure on maintenance hemodialysis remains controversial. The objective of this study was to determine the effectiveness and safety of digoxin at lower doses in patients with heart failure on maintenance hemodialysis using a retrospective cohort study. This study included 67 heart‑failure patients on maintenance hemodialysis: Twenty‑four patients received intermittent low doses of digoxin (ILDD), 23 patients received continuous low doses of digoxin (CLDD) and the remaining patients were used as a control group without digoxin treatment. The brain natriuretic peptide (BNP) level and serum digoxin concentrations (SDCs) were measured by ELISA and the changes in left ventricular end diastolic diameter (LVEDD), left ventricular ejection fraction (LVEF), cardiac output (CO) and heart rate (HR) were evaluated by two‑dimensional echocardiography. The symptoms of digoxin toxicity were monitored in the treated patients. Compared with the control group, LVEDD, BNP and HR decreased significantly between days 0 and 60 in the ILDD and CLDD groups, but LVEF and CO increased between days 0 and 60 in the same groups (all P<0.05). The levels of BNP and the LVEDD, CO, LVEF and HR were not significantly different between the ILDD and CLDD groups (P>0.05). Furthermore, and the mean SDC of the ILDD group was lower than that of the CLDD group. In the ILDD group, no patients had apparent symptoms of toxicity, but four patients developed digoxin toxicity in the CLDD group. In conclusion an intermittent lower dose of digoxin has beneficial effects and clinical safety in hemodialysis patients with congestive heart failure.

View Figures

View References

1	Pervaiz MH, Dickinson MG and Yamani M: Is digoxin a drug of the past? Cleve Clin J Med. 73:821–824. 826829–832. 2006. View Article : Google Scholar : PubMed/NCBI
2	Lambert C and Rouleau JL: How to digitalize and to maintain optimal digoxin levels in congestive heart failure. Cardiovasc Drugs Ther. 2:717–726. 1989. View Article : Google Scholar : PubMed/NCBI
3	Ahmed A and Waagstein F: Low-dose digoxin and reduction in mortality and morbidity in heart failure. Int J Cardiol. 136:91–92. 2009. View Article : Google Scholar : PubMed/NCBI
4	Ahmed A: Digoxin and reduction in mortality and hospitalization in geriatric heart failure: importance of low doses and low serum concentrations. J Gerontol A Biol Sci Med Sci. 62:323–329. 2007. View Article : Google Scholar : PubMed/NCBI
5	Digitalis Investigation Group. The effect of digoxin on mortality and morbidity in patients with heart failure. N Engl J Med. 336:525–533. 1997. View Article : Google Scholar : PubMed/NCBI
6	K/DOQI clinical practice guidelines on cardiovascular disease in dialysis patients: Overview of the epidemiology of cardiovascular disease. Am J Kidney Dis. 45(Suppl 3): S8–S9. 2005.
7	Chan KE, Lazarus JM and Hakim RM: Digoxin associates with mortality in ESRD. J Am Soc Nephrol. 21:1550–1559. 2010. View Article : Google Scholar : PubMed/NCBI
8	The Criteria Committee of the New York Heart Association. Nomenclature and Criteria for Diagnosis of Diseases of the Heart and Great Vessels. 9th ed. Little, Brown & Co; Boston, USA: pp. 253–256. 1994
9	Digitalis Investigation Group. Ahmed A, Waagstein F, Pitt B, et al: Effectiveness of digoxin in reducing one-year mortality in chronic heart failure in the Digitalis Investigation Group trial. Am J Cardio. 103:82–87. 2009.PubMed/NCBI
10	Ahmed A, Rich MW, Love TE, et al: Digoxin and reduction in mortality and hospitalization in heart failure: a comprehensive post hoc analysis of the DIG trial. Eur Heart J. 27:178–186. 2006. View Article : Google Scholar : PubMed/NCBI
11	Ahmed A, Pitt B, Rahimtoola SH, et al: Effects of digoxin at low serum concentrations on mortality and hospitalization in heart failure: a propensity-matched study of the DIG trial. Int J Cardiol. 123:138–146. 2008. View Article : Google Scholar : PubMed/NCBI
12	Iisalo E: Clinical pharmacokinetics of digoxin. Clin Pharmacokinet. 2:1–16. 1977. View Article : Google Scholar
13	Cayley WE Jr: Digoxin in chronic heart failure. Fam Pract. 21:469–475. 2004. View Article : Google Scholar

Journals

International Journal of Molecular Medicine

International Journal of Oncology

Molecular Medicine Reports

Oncology Reports

Experimental and Therapeutic Medicine

Oncology Letters

Biomedical Reports

Molecular and Clinical Oncology

World Academy of Sciences Journal

International Journal of Functional Nutrition

International Journal of Epigenetics

Medicine International

Intermittent low‑dose digoxin may be effective and safe in patients with chronic heart failure undergoing maintenance hemodialysis

This article is mentioned in:

Abstract

Figure 1

Related Articles